Clinical trial
Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma
NCT04383119 · Italian Sarcoma Group, Other · Recruiting
Key facts
| NCT number | NCT04383119 |
|---|---|
| Title | Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma |
| Official title | A Randomized Phase II Trial Comparing the Activity of trabectedIn vs Gemcitabine in Patients With Metastatic or Locally Advanced Leiomyosarcoma Pretreated With Conventional Chemotherapy |
| Acronym | ISG-ARTICLE |
| Lead sponsor | Italian Sarcoma Group, Other |
| Collaborators | PharmaMar Industry |
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leiomyosarcoma of Ovary, Soft Tissue Sarcoma |
| Intervention type | Drug |
| Interventions | Trabectedin, Gemcitabine, No Intervention: Observational Cohort |
| Enrollment | 100 |
| Start date | Oct 29, 2021 |
| Primary completion | Dec 31, 2025 |
| Completion | Dec 31, 2026 |
| First posted | May 12, 2020 |
| Last update posted | Jan 2, 2026 |
| Countries | Italy |
At a glance
- 10–99 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: